The message we've received from the doctors on the size of Emmett's tumor since starting this clinical trial last August has always been consistent: after initially shrinking ~25% in the first two months, the spot has remained stable. When Emmett had his March MRI we heard the same thing -- the spot was still approximately the same size as it's been since October. However, when we met with the doctors two weeks later the message had changed. At our early April clinic appointment they said that upon closer review the team had concluded that Emmett's spot
has still been slowly shrinking, and now it was officially small enough to officially re-classify Emmett as a "partial response" to this medicine. (In order to officially re-classify a patient they require two MRIs that both indicate at least a 25% reduction that are at least 8 weeks apart, so Emmett won't officially be reclassified until after his May MRI, assuming his spot hasn't gotten any larger.)
We were very excited to hear that Emmett's spot has continued to shrink! Another miracle to add to our list!
We hadn't realized the detailed requirements for a "partial response" classification -- we thought he was already considered a partial response. But we're not too concerned about the semantics -- news that the spot is continuing to shrink, albeit slowly, is welcome news indeed!
And then just this week we got an unexpected phone call from Dr. Hoffman. She wanted to let us know that one of the kids on Emmett's trial was just diagnosed with a secondary cancer: lymphoma. It's possible that the lymphoma is a side effect of their initial cancer treatment protocol. It's also possible that the medicine that Emmett's on caused the lymphoma. Unfortunately it's impossible to know conclusively given the very little available data, and that's the whole purpose of a clinical trial -- to measure treatment effectiveness and to monitor side effects.
And so here we are today -- with a medicine that is continuing to benefit Emmett, but that may give him another cancer (or worse).
Our next meeting with the medical team is on Monday. They're going to gather as much available data to share with us at that time, and then we'll decide on our path forward. Possible options include:
1. Continue the trial at Emmett's current dose.
2. Continue the trial at a reduced dose.
3. Discontinue the trial (and perhaps consider other therapies).
Some of the questions I have for the medical team are:
- What dose of Emmett's medicine was this patient on?
- How long had the patient been on the trial?
- What primary cancer did the patient have?
- What treatments did the patient have for the primary cancer?
- What were the risk factors for the above treatments? Was there an increased risk factor for a secondary lymphoma given the initial treatments?
- How many total kids have been on Emmett's clinical trial? How many of them have been on the trial longer than Emmett? And at what dose?
- Based upon the data available today, and assuming that this patient's lymphoma was caused by Emmett's medicine, what's the percentage chance of getting lymphoma? And at what length of time on the trial?
- What are the treatment options for a secondary lymphoma given the therapies Emmett has already had? And how effective might they be?
- Would a PET/CT or other imaging study help reveal whether there's still active tumor that needs further treatment?
- If we discontinue the trial, would Emmett be able to get more of this medicine if his tumor starts coming back?
- If we discontinue the trial, would the recommendation be "watch and wait", or would the doctors want us to consider another trial? If so, what?
As Dr. Chi has discussed with us many times, when a child has a malignancy that is threatening their well being, that malignancy presents the most immediate danger to the child, and doctors generally want to focus primarily on treating that condition rather than holding off therapy because of the other conditions that the treatment might cause. And in Emmett's case, we know that this therapy is effective against his greatest risk. So there's a part of you that doesn't want to stop the full frontal assault. At the same time, the thought that the medicine you're giving your child each day may give him another cancer really shakes you to the core.
And so here we are again, with big decisions, and very limited data, and Emmett's health and well being in the balance.
As always, we will make this a matter of fasting and prayer. We've been led and inspired by divine power in the past, and I'm confident that the Lord will walk with us again this time. I'm thankful for an opportunity to fast and pray this weekend for divine guidance, and we would welcome any and all to join us.
Thank you all for your prayers and faith!